Highest phase reached
Phase 4
First clinical trial
Jun 1, 1995First marketed drug
Feb 2, 1999First NDA
Feb 2, 1999Last known activity
Jan 5, 2024
Timeline
1980s
- Jan 1, 1987
Ligand Pharmaceuticals— Founded
1990s
- Jan 1, 1998
Seragen— Acquired
2000s
- Jan 1, 2008
Pharmacopeia— Acquired
- Jan 1, 2009
Metabasis— Acquired
- Dec 17, 2009
Neurogen Corporation— Acquired
2010s
- Jan 1, 2011
CyDex Pharmaceuticals— Acquired
- Jan 1, 2015
OMT— Acquired
- Jan 1, 2015
Salexis— Acquired
- Jul 23, 2019
Ab Initio Biotherapeutics, Inc.— Acquired
2020s
- Jul 24, 2020
abametapir— Marketing Organization
- Aug 11, 2020
Pfenex, Inc— Acquired - Sep 27, 2023
Novan, Inc.— Acquired
- Jan 5, 2024
Berdazimer— NDA Organization
Drugs by trial phase (35 distinct, 72 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 3 (6 own, 3 via acquisition)
Phase 2 (10 own, 9 via acquisition)
Phase 1 (2 own, 4 via acquisition)
Indications
Studied for
- Alopecia
- Alopecia Areata
- Breast Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Non-Small-Cell Lung
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Drug-Related Side Effects and Adverse Reactions
- Epilepsy
- Hepatitis
- Hepatitis A
- Hepatitis B
- Hepatitis B, Chronic
- Hepatitis, Chronic
- Hypercholesterolemia
- Hypertension
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Lung Neoplasms
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Non-Hodgkin
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Cutaneous
- Mycoses
- Mycosis Fungoides
- Osteoporosis
- Osteoporosis, Postmenopausal
- Parapsoriasis
- Parkinson Disease
- Psoriasis
- Psychomotor Agitation
- Renal Insufficiency
- Restless Legs Syndrome
- Rhinitis
- Rhinitis, Allergic
- Rhinitis, Allergic, Seasonal
- Sarcoma
- Sarcoma, Kaposi
- Sezary Syndrome
- Syndrome
Marketed drugs (5)
Subsidiaries (10 direct, 11 total across the full acquisition tree)
Recent trials (50)
- NCT04629976CollaboratorPhase 1Dec 31, 2020
- NCT04627831Lead sponsorPhase 2Dec 31, 2020
- NCT04627831Study directorPhase 2Dec 31, 2020
- NCT04629976Study directorPhase 1Dec 31, 2020
- NCT04309526CollaboratorPhase 1Mar 18, 2020
- NCT03869983Study directorN/AApr 12, 2019
- NCT03869983CollaboratorN/AApr 12, 2019
- NCT02851849Lead sponsorPhase 2Sep 1, 2016
- NCT02851849Study directorPhase 2Sep 1, 2016
- NCT02672839Lead sponsorPhase 1Feb 1, 2016
- NCT02250222Lead sponsorPhase 1Oct 1, 2014
- NCT02250222Study directorPhase 1Oct 1, 2014
- NCT01919684Lead sponsorPhase 1Nov 1, 2013
- NCT01128959CollaboratorPhase 3Jun 1, 2010
- NCT00879112Lead sponsorPhase 2Apr 1, 2009
Details
- Founded
- San Diego, CA, US Jan 1, 1987
- First NDA
- Feb 2, 1999
- Last known activity
- Jan 5, 2024
Designations held
- Orphan drug
- Priority review
Notes
Acquired Vernalis 9 Aug 2018 Crystal Bioscience 4 Oct 2017 OMT 18 Dec 2015 Selexis 11 May 2015 CyDex 27 Jan 2011 Neurogen 17 Dec 2009 Metabasis Therapeutics 27 Oct 2009 Pharmacopeia 24 Sep 2008